who we are

leadXpro’s scientists

Our scientists are experts in structural biology and/or their respective discipline and have up-to-date expertise in transmembrane protein projects and modern drug discovery.

All of them have a track records in succeeding with membrane protein structural biology projects. Here at LeadXpro they have access to a cutting-edge technology platform to tackle transmembrane protein structure-based drug discovery projects. Our scientists’ deep technical experience covers GPCRs, transporters and ion-channel targets.

Recently our team has been completed by experts for biophysical measurements and medicinal chemistry, enabling us to translate the biostructural results into valuable drug molecules.

Paul Scherrer Institute

The PSI runs Switzerland’s “large research facilities” for national and international scientists in academia and industry.

World renowned large research facility and home of 1,900 highly innovative national and international scientists. International membrane protein structural biology hub and home to the the Swiss Light Source SLS synchrotron X-ray instrument and the Free Electron Laser SwissFEL. (a Free Electron Laser).

leadXpro is a spin-off from the Paul Scherrer Institute. Its co-location fosters close collaborations with PSI scientists and provides direct access to the research facilities. Find out more about the Paul Scherrer Institute on the PSI website.

It is one of only two locations in the world providing the three complementary probes of synchrotron X-rays, neutrons and muons at one site. Read more about it on the PSI website. Most important for LeadXpro are the access to the Swiss Light Source SLS and the Free Electron Laser SwissFEL.

Bayer

Bayer is a Life Science company with a more than 150-year history and core competencies in the areas of health care and agriculture.

Bayer Healthcare’s research focuses on new therapies for the treatment of diseases where there is a high level of medical need, such as cancer and cardiovascular diseases.

Boehringer Ingelheim

The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies.

Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates globally with 145 affiliates and a total of around 47,500 employees. The focus of the family-owned company, founded in 1885, is researching, developing, manufacturing and marketing new medications of high therapeutic value for human and veterinary medicine. (from Boehringer’s global website)

On november 6, 2016 Boehringer Ingelheim and leadXpro AG announced their partnership to enable structure based drug discovery and the use of biophysical methods for projects with challenging membrane protein drug targets.

Heptares Therapeutics

Heptares is a clinical-stage company creating novel medicines targeting G protein-coupled receptors (GPCRs), a superfamily of receptors linked to a wide range of human diseases.

Heptares’ proprietary StaR® technology and structure-based drug design (SBDD) capabilities are enabling us to build an exciting pipeline of new medicines with potential to transform the treatment of Alzheimer’s disease, schizophrenia, cancer, migraine, metabolic disease, and other indications. Heptares’ ability to address highly validated, yet historically undruggable, GPCRs has also attracted multiple pipeline and technology partners including Allergan, AstraZeneca, Kymab, Morphosys, Pfizer and Teva. [cited from Heptares’ website].

Heptares is a wholly owned subsidiary of Sosei Group Corporation.

Center for Cellular Imaging and Nano-Analytics

The C-CINA is a research laboratory of the Biozentrum of the University of Basel, Switzerland.

The C-CINA research groups are led by Henning StahlbergJan Peter AbrahamsThomas Braun.

Research focus is on membrane protein structure / function relationships of and aggregation mechanisms involved in neurodegeneration relevant to Alzheimer’s and Parkinson’s disease.

Park INNOVAARE

Develops and offers newly established and relocating companies an exceptional support program to transform investments and technologies into marketable innovation.

Located in close proximity to the Paul Scherrer Institute (PSI) and its unique complex of large research facilities, Switzerland Innovation PARK INNOVAARE and the companies based there profit from the extensive collaboration opportunities with leading experts in four innovation focus areas: accelerator technology, advanced materials and processes, humans and health, and energy.

Salipro

Salipro® nanoparticles stabilise membrane proteins in a lipid environment and allow to work in detergent-free buffer systems

From Salipro’s webpage: Salipro® nanoparticles are formed via a defined self-assembly process.  The scaffold protein and lipids assemble around the membrane protein and reconstitute it in a nanoscale lipid environment. Using Salipro®, it is possible to work with membrane proteins as if they were soluble proteins. It is possible to incorporate various classes of membrane proteins into the Salipro® nanoparticles: Human, bacterial, viral, GPCR, channels, transporters, receptors etc.

alt text

Michael Hennig, Prof., PhD

CEO, Chairman of the Board

Structural biologist and senior Pharma drug discovery executive. Professor in structural biology at the University of Basel.

After his PhD at the EMBL Hamburg and a postdoc at the Biozentrum of the University of Basel Michael Hennig looks back to 20 years of drug discovery expertise in structural biology and research management at F. Hoffmann – La Roche AG Basel. Helped deliver Tamiflu, Fortovase, Xenical, Carmegliptin, Aleglitazar and is author of more than 70 articles and 8 patents. He holds a professorship position for  structural biology at the University of Basel.

Rafael Abela, PhD

Board of Directors

Physicist at the PSI, scientific project leader for the SLS and SwissFEL projects.

Scientific leader of the Swiss Light Source (SLS) project and project leader for photonics and research of the Swiss Free Electron Laser (SwissFEL) at the Paul Scherrer Institute PSI. More than 80 peer-reviewed publications

Pascale Bruderer Wyss, M.A.

Board of Directors

Member of the council of states (Ständerat) for the canton Aargau and member of various commissions of the council including safety and health. Extensive experience in cantonal and national charges as well as in startup and large companies.

After studying Politics and Law at University of Zürich, Växjö (Sweden) and Havard University Boston (USA), Pascale Bruderer Wyss began her career at UBS in finance roles and at Microsoft Switzerland as manager of social projects. She co-founded the company ’’machs! GmbH“ focusing on  communication, personnel and financial consultancy. She then had roles with increasing political responsibility from city council Baden 1997, council of the canton Aargau (election 2001), 2002 national council in Bern, 2009 president of the national council of Switzerland. Other appointments include the secretariat of the Swiss cancer foundation, the membership of the advisory Board of the Swiss Economic Forum and of the development location PARK INNOVAARE. Pascale Bruderer Wyss was elected „politician of the year” in 2010.

Martin Jermann

Board of Directors

Physicist, several management positions at the PSI including acting director function. Head of PSI proton therapy development program.

Physics studies at the ETH Zürich, Head of staff, PSI 1998-2012, head of PSI proton therapy development program 2000-2012, acting director of PSI 2007-2008

Christof Gerber, M.D.

Board Member

Christof holds a Master Degree in Economics and a MD of the University of Zurich. He currently works as a physician at the Institute of Anesthesiology and Pain Medicine at the University of Zurich.

During his medical training and between various medical assignments in Critical Care, Anesthesiology and Internal Medicine he completed Management Programmes at INSEAD in Fontainebleau and at Harvard Business School. He is an active board member in several small Swiss companies.

Andreas Insam, Dr. rer. soc. oec.

Board of Directors

Doctor in political economics, University of Innsbruck. CEO of Bendura Bank, previously Board member of LGT Bank. Lecturer at the Universities of Innsbruck and Liechtenstein.

Dr. Insam holds the qualification Dr. rer. soc. oec. from the University of Innsbruck. He has been CEO of BENDURA BANK AG since it was founded in 1998. He was previously a long-standing member of the Board of Managers of LGT Bank in Liechtenstein (Frankfurt) GmbH, responsible for the Institutional Sales division. After he obtained his doctorate in Business Administration, he served as Research Assistant at the University of Innsbruck’s Institute of Mathematics and Statistics, and later became Assistant to the Executive Board of LGT Bank in Liechtenstein. Andreas Insam has been a lecturer and examiner at the Universities of Liechtenstein and Innsbruck for many years.

Peter Nollert, PhD

Business Development USA

peter.nollert (at) leadxpro.com
Biochemist, expert in membrane protein methods and innovator in life science product development and commercialization.

Biochemist, studied at University of Tübingen, PhD in Membrane Proteins, spearheaded collaborative membrane protein structure research and business at Emerald Bio & Beryllium. International biopharma business professional.

Nicola Thompson, PhD

Business Development Europe

nicola.thompson(at)leadxpro.com
Cell Biologist, expert in drug discovery, business development and externalization of drug discovery in several big pharma companies.

PhD at University College London. Previously VP and Global Head of External Drug Discovery at F. Hoffmann-La Roche Ltd. Prior to this, Nicola was Senior Director, Business Development for GSK’s Centre of Excellence for External Drug Discovery (Ceedd), Head of Drug Discovery for Syntaxin Ltd. and Allergic Mechanisms head for GSK’s respiratory therapy area.

Gebhard Schertler, Prof., PhD

Chairman, Scientific Advisory Board

Biochemist, department head BIO and member of the Directorial Board of the Paul Scherrer Institute PSI.

MRC Cambridge, Department head of Biology and Chemistry at the PSI, Professor for Structural Biology at ETH Zürich

Bernd Kuhn, PhD

Computational chemist

Ph.D. in Physical Chemistry from EPF Lausanne, post-doc at UCSF, scientist at Prospect Genomics start-up, 15 years at Roche

Roche Senior Principal Scientist, 15 years of drug discovery experience, patents on 6 molecules having entered clinical stage, Leo Sternbach award and Roche patent gold medal, 84 patents and 69 publications

Henning Stahlberg, Prof., PhD

Expert Electron Microscopy

Structural biologist and Full Professor at the University of Basel. Director of the Center for Cellular Imaging and NanoAnalytics (C-CINA), Biozentrum, University of Basel, Switzerland.

Studied physics at TU Berlin, Germany, PhD in structural biology at the EPFL Lausanne, Switzerland, post-doc and habilitation in biophysics at the Biozentrum, University of Basel, Switzerland on transmission electron microscopy of proteins and protein complexes. Henning Stahlberg was professor for molecular & cellular biology at UC Davis, USA, from 2003-2010, and since 2009 is heading the Center for Cellular Imaging and NanoAnalytics (http://c-cina.unibas.ch) at the Biozentrum of the University of Basel. Author of more than 141 peer reviewed papers.

alt text

Michael Hennig, Prof., PhD

CEO, Chairman of the Board

Structural biologist and senior Pharma drug discovery executive. Professor in structural biology at the University of Basel.

After his PhD at the EMBL Hamburg and a postdoc at the Biozentrum of the University of Basel Michael Hennig looks back to 20 years of drug discovery expertise in structural biology and research management at F. Hoffmann – La Roche AG Basel. Helped deliver Tamiflu, Fortovase, Xenical, Carmegliptin, Aleglitazar and is author of more than 70 articles and 8 patents. He holds a professorship position for  structural biology at the University of Basel.

Paul Scherrer Institute

The PSI runs Switzerland’s “large research facilities” for national and international scientists in academia and industry.

World renowned large research facility and home of 1,900 highly innovative national and international scientists. International membrane protein structural biology hub and home to the the Swiss Light Source SLS synchrotron X-ray instrument and the Free Electron Laser SwissFEL. (a Free Electron Laser).

leadXpro is a spin-off from the Paul Scherrer Institute. Its co-location fosters close collaborations with PSI scientists and provides direct access to the research facilities. Find out more about the Paul Scherrer Institute on the PSI website.

It is one of only two locations in the world providing the three complementary probes of synchrotron X-rays, neutrons and muons at one site. Read more about it on the PSI website. Most important for LeadXpro are the access to the Swiss Light Source SLS and the Free Electron Laser SwissFEL.

Ernst Thomke, M.D.

Investor

Chemist and Physician, board member and investor of various biotech, medtech and machine industry companies.

After an apprenticeship in mechanics and subsequent studies of chemistry and medicine, Ernst Thomke gained experience in antibiotics research whilst at at Beecham (now GSK). After additional studies at the INSERM in Fontainebleau he had several positions in management of watch industry (ETA, SMH, Swatch Group), became then general director of SMH and restructured a number of companies including Pilatus and Saurer. Ernst Thomke is one of the inventors of the brand ‘Swatch’ which was instrumental in the resurgence of the swiss watch industry. Read more about him on Wikipedia.

Gebhard Schertler, Prof., PhD

Chairman, Scientific Advisory Board

Biochemist, department head BIO and member of the Directorial Board of the Paul Scherrer Institute PSI.

MRC Cambridge, Department head of Biology and Chemistry at the PSI, Professor for Structural Biology at ETH Zürich

Rafael Abela, PhD

Board of Directors

Physicist at the PSI, scientific project leader for the SLS and SwissFEL projects.

Scientific leader of the Swiss Light Source (SLS) project and project leader for photonics and research of the Swiss Free Electron Laser (SwissFEL) at the Paul Scherrer Institute PSI. More than 80 peer-reviewed publications

INSAM Familienstiftung

The foundation holds direct investments in several industries: banking (BENDURA BANK AG), commercial real estate and pharmaceuticals. The foundation’s beneficiaries are members of the INSAM Family.

Settlor of the INSAM FAMILIENSTIFTUNG is Dr. Andreas Insam. Its address is Austrasse 56, 9490 Vaduz, Liechtenstein